<DOC>
	<DOC>NCT01485601</DOC>
	<brief_summary>The purpose of this study is to find an optimal dose to determine the safety and tolerability of a single dose of MT10109(clostridium botulinum type A) administered by intramuscular injection in subjects with glabellar lines compared with the standard dose of BOTOXÂ®</brief_summary>
	<brief_title>Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Adults aged between 18 and 75 years with glabellar facial lines of at least moderate severity at maximum frown by investigator's assessment. Women of childbearing potential must have a negative serum pregnancy test at screening Patients with an inability to substantially lessen glabellar lines by physically spreading them apart. Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication Patients with an anaphylactic response history to botulinum toxin type A. Patients who have been administered botulinum toxin type A within the previous 6 months. Pregnant or lactating women. Participation in any research study involving drug administration within 90 days preceding enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>